NCM · Financial Statements

60 Degrees Pharmaceuticals, Inc. (SXTP) Financial Statements

$0.87 NCM: SXTP Market Cap $3.05M

60 Degrees Pharmaceuticals, Inc. most recently reported annual revenue of $1.0M, a net loss of $7.0M. Revenue declined at an average annual rate of 12.9% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

60 Degrees Pharmaceuticals, Inc.: Revenue fell from $2.0M in 2020 to $1.0M in 2025, a change of -50.0% over 5 years; net profit was positive in 0 of 6 reported years; operating margin moved from -19.2% to -771.6%, a shift of -752.5 percentage points; the most recent year shows a net loss of $7.0M.

Income Statement — 6 Years (USD millions)

Metric202020212022202320242025
Revenue$2.0M$1.0M$0$0$1.0M$1.0M
Operating Expenses$3.0M$2.0M$2.0M$5.0M$10.0M$9.0M
Operating Profit$0$-1.0M$-2.0M$-5.0M$-10.0M$-8.0M
Operating Margin-19.2%-96.9%-784.2%-2032.8%-1599.0%-771.6%
Other Income$-3.0M$-3.0M$-4.0M$1.0M$2.0M$0
Interest$3.0M$3.0M$4.0M$2.0M$0$0
Depreciation$0$0$0$0$0$0
Profit Before Tax$-3.0M$-4.0M$-6.0M$-4.0M$-8.0M$-7.0M
Tax$-30,000$-20,000$-10,000$-10,000$0$0
Net Profit$-3.0M$-4.0M$-6.0M$-4.0M$-8.0M$-7.0M
EPS$-2.08$-2.96$-4.28$-3.80$-74.20$-11.73
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

7 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$2.0M$2.0M$1.0M$4.0M$2.0M$2.0M$2.0M$2.0M$3.0M$2.0M$2.0M$2.0M
Operating Profit$-2.0M$-2.0M$-1.0M$-4.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M
Operating Margin-2972.9%-4435.3%-1270.4%-3351.8%-1566.0%-794.0%-1168.4%-1590.0%-531.4%-632.0%-1292.5%-1092.4%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$4.0M$-2.0M$0$-4.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-1.0M$-2.0M$-2.0M
Tax$0$0$10,000$-10,000$-10,000$20,000$0$-90,000$-10,000$130,000$0$0
Net Profit$4.0M$-2.0M$0$-4.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-1.0M$-2.0M$-2.0M
EPS$2.88$-1.36$7.32$-16.44$-3.52$-18.00$-6.24$-5.00$-2.52$-1.35$-1.28$-0.90

Over the 6 years reported for 60 Degrees Pharmaceuticals, Inc., borrowings decreased from $16.0M in 2020 to $0 in 2025, cash stood at $2.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.50 times.

Balance Sheet — 6 Years (USD millions)

Metric202020212022202320242025
Total Assets$3.0M$1.0M$1.0M$8.0M$6.0M$5.0M
Current Assets$2.0M$1.0M$1.0M$7.0M$5.0M$5.0M
Cash$0$0$0$2.0M$2.0M$2.0M
Inventory$1.0M$1.0M$1.0M$0$0$1.0M
Receivables$1.0M$0$0$0$0$1.0M
Fixed Assets$0$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0$0
Investments$0$0$0$0$2.0M$1.0M
Other Assets$0$0$0$0$0$0
Total Liabilities$21.0M$20.0M$25.0M$3.0M$2.0M$2.0M
Current Liabilities$1.0M$1.0M$24.0M$3.0M$2.0M$2.0M
Borrowings$16.0M$19.0M$22.0M$0$0$0
Other Liabilities$5.0M$1.0M$3.0M$3.0M$2.0M$2.0M
Equity$1.0M$5.0M$0$0$0$0
Reserves$-18.0M$-18.0M$-24.0M$5.0M$4.0M$3.0M

For 60 Degrees Pharmaceuticals, Inc., operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was negative at $7.0M; free cash flow was positive in 0 of 6 years.

Cash Flow Statement — 6 Years (USD millions)

Metric202020212022202320242025
Operating Cash Flow$0$-1.0M$-1.0M$-5.0M$-6.0M$-7.0M
Investing Cash Flow$0$0$0$0$-2.0M$0
Financing Cash Flow$0$0$0$1.0M$0$0
Net Cash Flow$0$0$0$2.0M$0$0
Free Cash Flow$0$-1.0M$-1.0M$-5.0M$-6.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.50
FCF Yield-183.08%
Quick Ratio1.78
Interest Coverage-1134.85
Return 1Y-77.86%
Return 3Y-99.83%
Return 5Y—

60 Degrees Pharmaceuticals, Inc. (SXTP) financials — frequently asked questions

What is 60 Degrees Pharmaceuticals, Inc.'s annual revenue?

60 Degrees Pharmaceuticals, Inc. (SXTP) reported annual revenue of $1.0M in its most recent fiscal year.

What is 60 Degrees Pharmaceuticals, Inc.'s net profit?

60 Degrees Pharmaceuticals, Inc. (SXTP) reported a net loss of $7.0M in its most recent fiscal year.

What is SXTP EV/EBITDA?

60 Degrees Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.50. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
SXTP Overview SXTP Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.